Influenza A H1N1 Intranasal and Peramivir Intravenous
Determining the interaction of Influenza A H1N1 Intranasal and Peramivir Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Antiviral flu medications like peramivir may interfere with the immune response to influenza virus vaccine, H1N1, live. Individuals who have been treated with antiviral flu medications should generally not be vaccinated with influenza virus vaccine, H1N1, live until 24 to 48 hours after stopping treatment. The immunizing doctor should be informed of recent therapy with peramivir so that appropriate measures and/or precautions can be taken. Similarly, individuals who have been vaccinated with influenza virus vaccine, H1N1, live must generally wait two weeks before using antiviral flu medications unless otherwise directed by their doctor. If vaccination was given shortly before or during treatment with an antiviral flu medication, a revaccination may be necessary at some point. It is important to tell the doctor about all other medications being used, including vitamins and herbs. Do not stop using any medications without first talking to the doctor.
Professional:ADJUST DOSING INTERVAL: Antiviral agents that are active against influenza A and/or B viruses may conceivably interfere with the immunogenicity of live influenza virus vaccine by inhibiting the replication of vaccine virus. However, the potential for interaction has not been evaluated.
MANAGEMENT: Live influenza virus vaccine should not be administered until at least 48 hours after the cessation of antiviral therapy. Antiviral agents should not be administered until two weeks after immunization with live influenza virus vaccine unless medically indicated. If antiviral agents and live influenza virus vaccine are administered concomitantly, revaccination should be considered when appropriate. The product labeling for zanamivir recommends waiting 24 hours after cessation of the drug before administration of live influenza virus vaccine.
- "Product Information. Relenza (zanamivir)" Glaxo Wellcome, Research Triangle Pk, NC.
- "Product Information. Xofluza (baloxavir marboxil)." Genentech, South San Francisco, CA.
- "Product Information. FluMist (influenza virus vaccine, live, trivalent)." Medimmune Inc, Gaithersburg, MD.
- "Product Information. Rapivab (peramivir)." BioCryst Pharmaceuticals Inc, Durham, NC.
- "Product Information. Influenza Virus Vaccine, H1N1, Live (influenza virus vaccine, H1N1, live)." Medimmune Inc, Gaithersburg, MD.
Generic Name: influenza virus vaccine, h1n1, live
Brand name:
Synonyms: n.a.
Generic Name: peramivir
Brand name: Rapivab
Synonyms: Peramivir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Influenza A H1N1 Intranasal-Perampanel
- Influenza A H1N1 Intranasal-Perampanel Oral Suspension
- Influenza A H1N1 Intranasal-Perampanel Tablets
- Influenza A H1N1 Intranasal-Peranex HC
- Influenza A H1N1 Intranasal-Percocet
- Influenza A H1N1 Intranasal-Percocet 10/325
- Peramivir Intravenous-Influenza A Vaccine
- Peramivir Intravenous-Influenza A Virus Vaccine (H5N1)
- Peramivir Intravenous-Influenza a virus vaccine, h1n1, inactivated Intramuscular
- Peramivir Intravenous-Influenza H1N1 Vaccine
- Peramivir Intravenous-Influenza Vaccine Live Intranasal
- Peramivir Intravenous-Influenza Vaccine Recombinant